Brimapitide: Molecular Structure

Molecular Structure#

Brimapitide is a synthetic fusion peptide designed with two functional domains linked by proline spacers. Its key structural feature is that all amino acids are in the D-configuration, making the peptide a mirror image of natural L-peptides.

Chemical Properties#

Domain Architecture#

TAT Cell-Penetrating Domain (C-terminal)#

The TAT domain consists of the sequence dR-dK-dK-dR-dQ-dR-dR-dR, a retro-inverso version of the HIV-1 transactivator of transcription (TAT) protein transduction domain. This highly cationic sequence enables the peptide to:

• Cross cell membranes via multiple uptake mechanisms
• Penetrate into the cytoplasm and nucleus
• Deliver the attached JNK inhibitor domain intracellularly

Proline Spacers#

Two D-proline residues separate the TAT domain from the effector domain, providing:

• Structural flexibility between the two functional domains
• A break in secondary structure to allow independent folding
• Optimal presentation of each domain for its respective function

JNK Binding Domain (N-terminal)#

The 19-amino acid effector domain is derived from the JNK-binding domain of the scaffold protein IB1/JIP1 (islet-brain 1/JNK-interacting protein 1). This domain:

• Competitively binds to the JNK docking site
• Blocks JNK from phosphorylating its downstream substrates (c-Jun, ATF2, Elk-1)
• Does not inhibit JNK kinase activity directly but prevents substrate access

D-Amino Acid Configuration#

The use of all D-amino acids is a critical design feature:

• Protease resistance: D-peptides are not recognized by natural proteases, dramatically extending intracellular half-life
• Retro-inverso design: The peptide sequence is reversed compared to the L-amino acid version, resulting in a topochemically similar molecule that retains biological activity
• Extended duration: A single dose provides prolonged JNK inhibition without the need for repeated administration

Formulation#

Brimapitide was formulated in a biocompatible, biodegradable hyaluronic acid gel for intratympanic injection. This gel formulation:

• Provides sustained release of the peptide to the round window membrane
• Allows drug diffusion into the inner ear (cochlea)
• Is fully biodegradable and does not require removal
• Enables single-dose administration

Molecular Context#

Brimapitide belongs to the Healing category of research peptides. The molecular properties of Brimapitide determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.

Structural Overview#

Brimapitide is characterized as: Brimapitide is a 31-amino acid peptide composed entirely of D-amino acids. It consists of a 10-residue TAT cell-penetrating domain connected by two D-proline spacers to a 19-residue JNK binding domain derived from the scaffold protein IB1/JIP1. The D-amino acid composition confers resistance to enzymatic degradation..

Amino Acid Sequence Details#

The amino acid sequence of Brimapitide is: dR-dP-dK-dR-dP-dT-dT-dL-dN-dL-dF-dP-dQ-dV-dP-dR-dS-dQ-dD-dT-dD-dP-dP-dR- dK-dK-dR-dQ-dR-dR-dR (all D-amino acids). This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.

Pharmacokinetic Profile#

Half-Life: Extended intracellular half-life due to D-amino acid composition (resistant to proteolysis). Exact value not publicly disclosed.

The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.

Related Reading#

• Brimapitide overview and research guide
• Peptides similar to Brimapitide
• Brimapitide research evidence